Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • Sex Differences in Medicine (Sep 2024)
    • Vascular Malformations (Apr 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Top
  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal
  • Top
  • Abstract
  • Version history
  • Article usage
  • Citations to this article

Advertisement

Research Article Free access | 10.1172/JCI110046

Protoporphyrin-induced Cholestasis in the Isolated In Situ Perfused Rat Liver

Dennis L. Avner, Randall G. Lee, and Malcolm M. Berenson

Division of Gastroenterology, Department of Internal Medicine, University of Utah College of Medicine, Salt Lake City, Utah 84132

Division of Gastroenterology, Department of Pathology, University of Utah College of Medicine, Salt Lake City, Utah 84132

Salt Lake City Veterans Administration Medical Center, Salt Lake City, Utah 84148

Find articles by Avner, D. in: PubMed | Google Scholar

Division of Gastroenterology, Department of Internal Medicine, University of Utah College of Medicine, Salt Lake City, Utah 84132

Division of Gastroenterology, Department of Pathology, University of Utah College of Medicine, Salt Lake City, Utah 84132

Salt Lake City Veterans Administration Medical Center, Salt Lake City, Utah 84148

Find articles by Lee, R. in: PubMed | Google Scholar

Division of Gastroenterology, Department of Internal Medicine, University of Utah College of Medicine, Salt Lake City, Utah 84132

Division of Gastroenterology, Department of Pathology, University of Utah College of Medicine, Salt Lake City, Utah 84132

Salt Lake City Veterans Administration Medical Center, Salt Lake City, Utah 84148

Find articles by Berenson, M. in: PubMed | Google Scholar

Published February 1, 1981 - More info

Published in Volume 67, Issue 2 on February 1, 1981
J Clin Invest. 1981;67(2):385–394. https://doi.org/10.1172/JCI110046.
© 1981 The American Society for Clinical Investigation
Published February 1, 1981 - Version history
View PDF
Abstract

The pathogenesis of liver disease in protoporphyria has been presumed to result from the hepatic deposition of protoporphyrin. To examine the effects of protoporphyrin on hepatic bile flow and histopathology, studies were performed employing an isolated, in situ, rat liver perfusion system. Rat livers in the control group were perfused with 0-80 μmol sodium taurocholate/h. Rat livers in the experimental group were perfused with sodium taurocholate and (a) sufficient quantities of protoporphyrin to produce maximal canalicular secretion and (b) perfusate protoporphyrin concentrations of 0.01, 0.1, and 1 μM.

The administration of protoporphyrin sufficient to achieve maximal canalicular secretion was found to significantly reduce bile flow in rats infused with 0, 40, and 80 μmol sodium taurocholate/h. Linear regression analysis defined the relationship between bile flow and biliary bile acid secretion and showed that the bile acid-independent fraction of bile flow was reduced (P < 0.01). Bile acid-dependent flow was unaffected and there was no significant difference in biliary bile acid secretion rates between control and protoporphyrin-perfused livers. Perfusion of rat livers with varying concentrations of protoporphyrin demonstrated the reduction of bile flow was dose-related. Analysis of perfusate enzyme activity did not reveal abnormalities that could account for the cholestasis. Studies to evaluate the effect of protoporphyrin on regional hepatic hemodynamics were inconclusive.

Histopathological studies of control and protoporphyrin-perfused rat livers did not show abnormalities on light microscopy. However, canalicular dilatation, distortion, and loss of microvilli were present in the protoporphyrin-perfused livers examined by transmission electron microscopy. Although ultraviolet microscopy showed diffuse fluorescence of the hepatocytes and canaliculi of protoporphyrin-perfused livers, the deposition of protoporphyrin in amorphous or crystalline forms was notably absent in studies with polarizing and transmission electron microscopy.

These studies provide evidence that protoporphyrin has hepatotoxic properties that affect the canalicular secretory apparatus. The mechanism(s) responsible for the injury require further clarification.

Images.

Browse pages

Click on an image below to see the page. View PDF of the complete article

icon of scanned page 385
page 385
icon of scanned page 386
page 386
icon of scanned page 387
page 387
icon of scanned page 388
page 388
icon of scanned page 389
page 389
icon of scanned page 390
page 390
icon of scanned page 391
page 391
icon of scanned page 392
page 392
icon of scanned page 393
page 393
icon of scanned page 394
page 394
Version history
  • Version 1 (February 1, 1981): No description

Article tools

  • View PDF
  • Download citation information
  • Send a comment
  • Terms of use
  • Standard abbreviations
  • Need help? Email the journal

Metrics

  • Article usage
  • Citations to this article

Go to

  • Top
  • Abstract
  • Version history
Advertisement
Advertisement

Copyright © 2025 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts